Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179400 · ClinicalTrials.gov registry record · Phase 4
The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
A Phase 4 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT00179400 is a Phase 4 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 26 participants.
The verdict
NCT00179400, a Phase 4 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the acute effects of the thiazolidinedione agent pioglitazone (which has combined PPAR alpha and gamma stimulation) on insulin's ability to suppress glucose production, stimulated glucose uptake, and impact a number of other metabolically important endpoints, including production of adiponectin (a protein hormone which regulates sugar levels and fatty acid breakdown) in subjects with type 2 diabetes.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- PROCEDURE Pancreatic Clamp Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2000-12 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179400
The ClinicalTrials.gov registry entry for NCT00179400 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00179400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179400 about?
NCT00179400 is a clinical study titled "The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans". The purpose of this study is to investigate the acute effects of the thiazolidinedione agent pioglitazone (which has combined PPAR alpha and gamma stimulation) on insulin's ability to suppress glucose production, stimulated glucose uptake, and impact a number of other metabolically important endpoin...
What is the current status of trial NCT00179400?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2000-12. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00179400?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Pancreatic Clamp Study (PROCEDURE).
Who is sponsoring clinical trial NCT00179400?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.